CWP232291 + cytarabine

CWP232291 + cytarabine is an experimental combination therapy being investigated primarily for hematologic malignancies, particularly acute myeloid leukemia (AML). **CWP232291** is a small-molecule prodrug that is rapidly converted in vivo to its active metabolite (CWP232204), which inhibits the Wnt/β-catenin pathway and induces apoptosis via modulation of several targets central to cancer cell survival, including β-catenin degradation and alternative splicing of apoptosis-related genes. **Cytarabine** is a well-established nucleoside analog antimetabolite used in the chemotherapeutic management of AML that incorporates into DNA and inhibits DNA synthesis, leading to cell death. Preclinical evidence and early-phase clinical trials support the biological rationale for combining these agents, with CWP232291 potentially overcoming therapeutic resistance to cytarabine through complementary action on oncogenic signaling pathways.